Table 1 Studies reviewed
Author and country | Population | Study design |
|---|---|---|
Altschuler, A. et al. [23], United States | 51 women at increased risk according to Gail model* and eligible for chemoprevention trial | Semi-structured in-depth in-person interviews |
Bober, S. L., et al. [24], United States | 129 increased–risk women according to Gail model* following cancer risk counselling | Self-administered questionnaires and telephone interviews at 2 and 4 months post-counselling |
Cyrus-David, M. et al. [39], United States | 26 women at increased risk | Qualitative study reporting focus group data |
Dillard, A.J., et al. [15] & Dillard, A. J., et al. [32], United States | 632 women at increased risk based on Gail model* score risk who were administered a decision aid | Self-administered questionnaires before and after reading decision aid |
Donnelly, L.S. [1], United Kingdom | 30 women at high risk (≥17% lifetime risk according to Tyrer-Cuzick model) ascertained through a high-risk clinic | Semi-structured interviews |
Fagerlin, A., et al. [9] & Fagerlin, A., et al. [29], United States | 663 women at increased risk according to Gail model* recruited through large health maintenance organizations | Self-administered questionnaires at baseline, post-decision aid and 3 months post-decision aid |
Fallowfield, L., et al. [11], United Kingdom | 488 women at high familial risk considering entry into chemoprevention trials | Self-administered questionnaires every 6 months |
Goldenberg, V. K. [18], United States | 99 women at increased risk according to Gail model* attending a clinic for high-risk breast cancer who received fine needle aspiration results designed to evaluate breast cancer risk | Women were followed up regarding the impact of their cytology results on decision-making pertaining to the use of tamoxifen for breast cancer chemoprevention |
Heisey, R., et al. [8], Canada | 27 women at increased risk | Semi-structured in-person interviews |
Julian-Reynier, C, et al. [19], Canada, United Kingdom and France | 355 women attending genetic clinics in Marseille, (n = 141), Manchester (n = 130) and Quebec (n = 84) | Self-administered questionnaire before consultation, consultant completed questionnaire after consultation |
Julian-Reynier, C., et al. [25], France | 246 carriers and non-carriers who were tested for BRCA1/2 mutations 5 years prior | Six self-administered questionnaires over 5 years |
175 women at increased risk for breast cancer who attended an information session about a breast cancer prevention trial and discussed participation with their physician | Self-administered questionnaire | |
Loehberg, C.R., et al. [40], Germany | 199 women at increased risk according to Tyrer–Cuzick model who were eligible for but declined participation in a chemoprevention trial | Self-administered questionnaire |
Matloff, E.T., et al. [30], United States | 48 cancer-free women with a first-degree relative with breast cancer | Self-administered questionnaires at baseline, 1 and 6 months, participants randomized to a genetic counseling intervention or control |
McKay, A., et al. [14], Canada | 51 women at high risk of breast cancer according to Gail model* and seen by surgeons | Self-administered questionnaire |
McKinnon, W. [41], Canada | 34 BRCA1/2 mutation carriers invited to a one-day retreat | Self-administered questionnaires at baseline and 6 months |
Meiser, B. [26], Australia | 371 women from multiple-case breast cancer families | Self-administered questionnaire |
Melnikow, J., et al. [12], United States | 255 women at increased risk according to Gail model* recruited through university medical center and at community sites | Qualitative and quantitative in-person interview |
Metcalfe, K. A., et al. [2], Canada | 81 BRCA1/2 mutation carriers who were identified through the records of two cancer genetics clinics | Mailed, self-administered questionnaire |
Muir, A. [20], Australia | 35 women who had attended a familial cancer clinic and were eligible for a chemoprevention trial were contacted 6 months - 7 years after clinic attendance | Structured telephone interview |
Paterniti, D.A. et al. [27], United States | 27 high-risk women (African-American, White, and Latina) sampled through community organizations | 3 separate focus group interviews with African- American, White, and Latina women plus post-focus group self-administered questionnaire |
Port, E.R. [38], United States | 43 at increased risk eligible to take tamoxifen for primary prevention* | Completion of baseline self-administered questionnaire, followed by educational sessions and literature on tamoxifen use, followed by questionnaire and telephone interview |
Razzaboni, E., et al. [10], Italy | 471 women at increased risk eligible for chemoprevention trial | Semi-structured interviews |
Rondanina, G. et al. [42], Italy | 457 women on hormone replacement therapy who were invited to participate in a low-dosage tamoxifen trial | Self-administered questionnaire |
Salant, T. et al. [21], United States | 33 high-risk women (75% African-American) recruited through a high-risk breast cancer clinic | Semi-structured interviews |
Schwartz, M. D., et al. [7], United States | 465 women who had genetic counselling and testing through clinical genetics research program | Choice of mailed self-administered survey or telephone survey |
Stacey, D., et al. [16], United States | 97 high-risk women with a 1.66% or greater five year, referred a high-risk breast assessment clinic | Mailed, self-administered questionnaire |
Taylor, R et al. [31], Canada | 89 women at high risk who were evaluated for a breast lump at a referral center | Telephone survey |
Tchou, J. et al. [43], United States | 137 women attending a breast center who were offered tamoxifen | Review of medical files |
Tjia, J., et al. [34], United States | 457 community dwelling women aged 60–65 years old who were potentially eligible for breast cancer chemoprevention according to Gail model* | Mailed, self-administered survey |
Underhill, M.L. [22], United States | 21 women at high risk recruited from a high-risk breast program | In-depth interviews |